Rezolute (RZLT) Expected to Announce Quarterly Earnings on Thursday

Rezolute (NASDAQ:RZLT) is expected to be releasing its Q1 2026 results before the market opens on Thursday, November 6th. Analysts expect Rezolute to post earnings of ($0.27) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 6:00 PM ET.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Stock Down 2.2%

RZLT stock opened at $8.90 on Wednesday. The stock has a market capitalization of $808.39 million, a price-to-earnings ratio of -9.18 and a beta of 0.07. Rezolute has a 52-week low of $2.21 and a 52-week high of $10.04. The stock’s fifty day simple moving average is $8.50 and its 200-day simple moving average is $6.11.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Rezolute in the second quarter valued at about $25,000. Legal & General Group Plc acquired a new position in shares of Rezolute in the 2nd quarter valued at approximately $32,000. Raymond James Financial Inc. acquired a new position in shares of Rezolute in the 2nd quarter valued at approximately $46,000. New York State Common Retirement Fund purchased a new position in shares of Rezolute during the 2nd quarter valued at approximately $104,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Rezolute during the 2nd quarter valued at approximately $106,000. Institutional investors and hedge funds own 82.97% of the company’s stock.

Analyst Upgrades and Downgrades

RZLT has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $12.00 price target on shares of Rezolute in a report on Thursday, September 18th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Wednesday, September 3rd. Maxim Group upped their price target on shares of Rezolute from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a report on Wednesday, October 8th. Finally, Guggenheim reissued a “buy” rating and set a $15.00 price objective on shares of Rezolute in a research note on Monday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Rezolute presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.